Glenmark launches generic Inlyta in the US market.
Glenmark Pharmaceuticals Limited GLENMARK has launched the authorized generic of Inlyta (axitinib) tablets in 1 mg and 5 mg strengths in the US. The drug has annual US sales of $538.4 million. The company introduced the authorized generic versions of Inlyta tablets. Strengths available are 1 mg and 5 mg. The product targets a US market with $538.4 million in annual sales and expands Glenmark’s oncology portfolio in the regulated market. The key number is the $538.4 million annual US sales of the reference product. This may support near-term interest in the stock on US generic launches. Peers such as Sun Pharmaceutical, Dr. Reddy's Laboratories and Aurobindo Pharma could face relative comparison on US product pipeline. Risks include pricing pressure or limited exclusivity. Competitors listed: Sun Pharmaceutical, Dr. Reddy's Laboratories, Aurobindo Pharma. We have no financial interest in this news.



















